For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.
Mobile stroke units equipped with clot busting medications, CT machines, and video connections to a physician are linked to better patient outcomes, including stroke avoidance, vs traditional EMS.
Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.